Vor Biopharma (VOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkcan from JMP Securities reiterated a Buy rating on the stock and has a $12.00 price target.
Silvan Tuerkcan has given his Buy rating due to a combination of factors demonstrating Vor Biopharma’s potential and progress in clinical trials. The company’s financial position is solid, with a cash balance that can support operations well into the second half of 2025, providing a stable runway for ongoing research and development. The momentum seen in the number of patients dosed with trem-cel, now including a higher dose level, indicates a promising advancement in the trial’s progression. Additionally, the expansion of the trem-cel trial to include Myelodysplastic Syndromes (MDS) patients significantly broadens the potential impact and market opportunity for Vor’s therapies.
Furthermore, early dosing in the VBP301 trial with VCAR33ALLO and overlapping sites with trem-cel trials suggest efficiency and synergy in their clinical approach. Tuerkcan is encouraged by the engraftment and tolerance observed at the highest Mylotarg dose tested and anticipates meaningful efficacy signals in the latter half of 2024. The potential for improved outcomes through additional Mylotarg cycles and the prospect of combining trem-cel with CD33-directed CAR-T therapy in cases of relapse are additional reasons for optimism. The early expansion into treating MDS patients underscores the strategic move to address a larger patient demographic, which could significantly enhance Vor Biopharma’s market presence and, in turn, investor confidence.
According to TipRanks, Tuerkcan is a 4-star analyst with an average return of 7.9% and a 37.15% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as MacroGenics, Crispr Therapeutics AG, and Elevation Oncology.
In another report released today, Barclays also maintained a Buy rating on the stock with a $10.00 price target.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Vor Biopharma (VOR) Company Description:
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.
Read More on VOR:
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Vor Biopharma Welcomes Oncology Expert to Board of Directors
- Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
- Vor Bio to Participate in Upcoming Investor Conferences
- Vor Bio price target lowered to $12 from $15 at Stifel
